Arrowstreet Capital
SGMO

Arrowstreet Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Arrowstreet Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-159,002
Closed -$779K – 1450
2022
Q3 		$779K Buy
159,002
+145,983
+1,121% +$750K ﹤0.01% 1030
2022
Q2 		$54K Buy
+13,019
New +$56.3K ﹤0.01% 1200
2021
Q1 		– Sell
-98,603
Closed -$1.54M – 2498
2020
Q4 		$1.54M Sell
98,603
-71,297
-42% -$835K ﹤0.01% 1691
2020
Q3 		$1.61M Buy
169,900
+99,331
+141% +$1.07M ﹤0.01% 1653
2020
Q2 		$632K Sell
70,569
-1,231
-2% -$11.4K ﹤0.01% 1909
2020
Q1 		$457K Buy
+71,800
New +$533K ﹤0.01% 1549
2018
Q2 		– Sell
-234,064
Closed -$4.45M – 1280
2018
Q1 		$4.45M Buy
+234,064
New +$5M 0.01% 596
2016
Q4 		– Sell
-90,522
Closed -$419K – 2394
2016
Q3 		$419K Buy
+90,522
New +$460K ﹤0.01% 1287
2014
Q3 		– Sell
-18,329
Closed -$280K – 1105
2014
Q2 		$280K Buy
+18,329
New +$264K ﹤0.01% 886
2013
Q4 		– Sell
-15,239
Closed -$160K – 1275
2013
Q3 		$160K Buy
+15,239
New +$151K ﹤0.01% 915

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital's SGMO Position: Q4 2022 in Review

Arrowstreet Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 159,002 shares — an estimated $779K sold.

Arrowstreet Capital first reported a position in SGMO in Q3 2013 and held it in 10 quarters. The position peaked at $4.45M in Q1 2018. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • Arrowstreet Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 159,002 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $779K.
  • Arrowstreet Capital first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 10 quarters.
  • Arrowstreet Capital's SANGAMO THERAPEUTICS INC position peaked at $4.45M in Q1 2018.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on Arrowstreet Capital's 13F filing for Q4 2022, filed 14 Feb 2023.